Back to Newsroom
Back to Newsroom

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PEGA, FHS and SPRO

Friday, July 8, 2022 9:45 AM
The Gross Law Firm
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / July 8, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Pegasystems Inc. (NASDAQ:PEGA)

This lawsuit is on behalf of all persons and entities that purchased PEGA common stock between May 29, 2020 and May 9, 2022, inclusive.

A class action has commenced on behalf of certain shareholders in Pegasystems Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) PEGA had engaged in corporate espionage and misappropriation of trade secrets to better compete against Appian, a principal competitor; (2) defendants' product development and associated success was, in significant part, not the result of its own research and product testing but rather the result of such corporate espionage and trade secret theft; (3) defendants had engaged in a scheme to steal Appian trade secrets, which was not only known to, but carried out through, the personal involvement of the Company's CEO; (4) the Company's CEO and other officers and employees did not comply with the Company's written Code of Conduct, including its express prohibition on "stealing" confidential information from a competitor and "misrepresenting your identity in hopes of obtaining confidential information"; (5) the Company was "unable to reasonably estimate damages" in the lawsuit filed by Appian as a result of the foregoing misconduct (the "Appian Litigation"); and (6) as a result of the foregoing, defendants' statements about PEGA's business, operations, prospects, legal compliance, and potential damages exposure in the Appian Litigation were materially false and/or misleading and/or lacked a reasonable basis when made.

Shareholders may find more information at https://securitiesclasslaw.com/securities/pegasystems-inc-loss-submission-form/?id=29671&from=1

First High-School Education Group Co., Ltd. (NYSE:FHS)

This lawsuit is on behalf of all persons or entities who purchased FHS American Depositary Shares in or traceable to the Company's March 2021 initial public offering.

A class action has commenced on behalf of certain shareholders in First High-School Education Group Co, Ltd. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the new rules, regulations and policies to be implemented by the Chinese government following the Two Sessions parliamentary meetings were far more severe than represented to investors and posed a material adverse threat to the Company and its business; (b) contemplated Chinese regulations and rules regarding private education were leading to a slowdown of government approval to open new educational facilities which would have a negative effect on FHS's enrollment and growth; and (c) as a result, representations made in connection with the Company's initial public offering regarding FHS's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company at the time of the initial public offering, and were materially false and misleading and lacked a factual basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/first-high-school-education-group-co-ltd-loss-submission-form/?id=29671&from=1

Spero Therapeutics, Inc. (NASDAQ:SPRO)

Investors Affected : October 28, 2021 - May 2, 2022

A class action has commenced on behalf of certain shareholders in Spero Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/spero-therapeutics-inc-loss-submission-form/?id=29671&from=1

The Gross Law Firm, Friday, July 8, 2022, Press release picture

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE : The Gross Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom